Pegylated interferon alpha-2a (40 kDa) in the treatment of chronic hepatitis B by Lai, Lawrence et al.
255
r e v i e w
international Journal of Nanomedicine 2006:1(3) 255–262
© 2006 Dove Medical Press Limited. All rights reserved
Abstract: Chronic hepatitis B virus (HBV) is a serious and life-threatening disease afflicting 350 
million of the world’s population. So far, current monotherapy with conventional interferon-alpha, 
lamivudine, and adefovir dipivoxil remains unsatisfactory. In addition, the use of conventional 
interferon-alpha needs to be administered subcutaneously daily or thrice weekly and is associated 
with frequent adverse events. Although nucleoside–nucleotide analogs such as lamivudine and 
adefovir dipivoxil are well tolerated and can normalize serum alanine aminotransaminase rapidly, 
1-year therapy with either lamivudine or adefovir dipivoxil results in low hepatitis B e antigen 
(HBeAg) seroconversion rates. In HBeAg negative patients, most of the patients would relapse 
after lamivudine has been discontinued. Pegylated interferon alpha-2a, an immunomodulatory 
agent, is a new drug that has just completed phase III clinical trials for the treatment of both 
HBeAg positive and HBeAg negative chronic HBV infection. The advantage of pegylated 
interferon alpha-2a in achieving sustained virological response over nucleoside–nucleotide 
analogs is particularly obvious in the HBeAg negative group. In both of these phase III studies, 
sustained off-treatment response is superior to the use of lamivudine. These recent data put 
pegylated interferon alpha-2a as the first choice of anti-HBV therapy, especially in young and 
motivated patients with chronic HBV infection. 
Keywords: pegylated interferon alpha-2a, chronic hepatitis B, HBeAg seroconversion, sustained 
virological response
Introduction
Hepatitis B virus (HBV) infection is one of the most common viral infections in 
humans. Approximately 2 billion people have been infected with HBV and 350 million 
of them became chronically infected. Individuals with chronic hepatitis B infection 
are at an increased risk of developing liver cirrhosis, hepatic decompensation, and 
hepatocellular carcinoma (HCC); 15%–40% of these individuals will develop these 
serious sequelae during their lifetime (Beasley 1988; McMahon  1997). Drugs that 
are currently approved by the Federal Drug Administration (FDA) for the treatment 
of chronic HBV consist of two groups: the immunomodulators such as conventional 
interferon alpha and pegylated interferon alpha-2a, and nucleoside–nucleotide analogs 
such as lamivudine, adefovir dipivoxil, and entecavir. However, not all patients with 
chronic hepatitis B infection respond to these treatments. 
The currently approved antiviral regimens, especially the nucleoside–nucleotide 
analogs, have been shown to improve the short-term outcome of disease but lack the 
ability to provide cure or induce durable remission in most patients with chronic HBV 
(Lee 1997). Lamivudine, the first nucleoside–nucleotide analog to be approved for the 
treatment of chronic HBV , has a favorable safety profile but long-term therapy with this 
drug can lead to the selection of drug-resistant mutants (Wong et al 1993; Niederau 
et al 1996). The risk of mutation increases with the duration of treatment. At the end 
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of the first, second, third, and fourth year of treatment, the 
incidences of resistance are: 15%–32%, 38%, 56%, and 67% 
respectively (Leung 2002). Adefovir dipivoxil is another oral 
nucleoside–nucleotide analog that requires long-term therapy. 
Initial reports show that adefovir dipivoxil selects resistant 
mutants in only a limited proportion of patients, but adefovir-
resistant mutants do occur at cumulative rate of 18% by 192 
weeks (Locarnini et al 2005).
A phase III study on entecavir showed that entecavir is 
superior to lamivudine in hepatitis B e antigen (HBeAg) 
positive and HBeAg negative nucleoside–nucleotide naïve 
patients (Chang et al 2004; Shouval et al 2004). Entecavir, 
with its profound suppression of serum HBV DNA, has less 
risk of resistance over time with no resistance at 96 weeks in 
HBeAg positive lamivudine-naïve patients (Gish et al 2005). 
Entecavir resistance in lamivudine-resistant patients is 7% 
genotypically and 1% phenotypically at 1 year. But follow-
up studies to determine the resistance rate after 2–5 years 
of therapy are required, especially in lamivudine-resistant 
patients. Another major limit is the lack of knowledge 
on how long nucleoside–nucleotide therapy needs to be 
continued, especially in HBeAg negative patients. This group 
of patients has been shown to have persistent benefit with 
144 weeks of adefovir dipivoxil therapy (Hadziyannis et al 
2005). Furthermore, sustained response after withdrawal of 
entecavir has also been shown to be less than optimal in both 
HBeAg positive and HBeAg negative patients (Chang et al 
2005; Lai et al 2005). Therefore, in view of the limitations of 
current therapies for chronic HBV , there is a need to develop 
new agents for the treatment of chronic HBV infection with 
improved efficacy. 
Immunomodulators
Conventional interferon alpha
Conventional interferon alpha-2b is the first drug to be 
approved by the FDA for treatment of chronic HBV infection. 
However, the efficacy of conventional interferon alpha, 
defined as sustained loss of HBeAg and HBV DNA, is 
limited. In a meta-analysis of 15 randomized, controlled trials, 
loss of HBeAg and HBV DNA in HBeAg positive patients 
is seen in 33% and 37% on conventional interferon alpha-
treated patients compared with 12% and 17% of untreated 
patients, respectively
 (Wong et al 1993). The studies reviewed 
in this meta-analysis employed direct spot hybridization 
for the detection of serum HBV DNA. In Caucasians, the 
long-term durability of HBeAg is as high as 90%
 (Niederau 
et al 1996), while around 20%–70% of patients with loss of 
HBeAg and hepatitis B e antibody (anti-HBe) seroconversion 
will eventually lose hepatitis B surface antigen (HBsAg)
 
(Niederau et al 1996; Lau et al 1997). In those with detectable 
HBV DNA after HBeAg seroconversion, the HBV DNA will 
be undetectable in 60%–100% of those who lose HBsAg.
In HBeAg negative variants (precore mutants and others), 
prolonged interferon at a dose of 3–5 MU thrice weekly 
for at least 12 months results in a sustained biochemical 
remission in 15%–25% of patients
 (Manesis and Hadziyannis 
2001; Papatheodoridis and Hadziyannis 2001). Factors that 
predict a favorable response to conventional interferon alpha 
include low pretreatment level of HBV DNA (< 200 pg/ml), 
high levels of serum aminotransaminase (> 100 U/L), and 
evidence of necroinflammatory activities in the liver
 (Brook 
et al 1989). In contrast, male sex, length of chronic state, 
Asian origin, precore mutants, and human immunodeficiency 
virus coinfection are factors associated with poor response 
to conventional interferon alpha
 (Schiff 1993). In a recent 
study from Taiwan, patients with genotype B were more 
likely to respond to conventional interferon alpha than 
those with genotype C
 (Kao et al 2000). A small study on 
the use of conventional interferon beta at 3 MU weekly for 
24 weeks also showed a 50% HBeAg seroconversion rate 
similar to that achieved with conventional interferon alpha
 
(Kagawa et al 1993). However, conventional interferon beta 
has never been recommended for use as a first-line agent for 
the treatment of chronic HBV due to a lack of large-scale 
randomized studies.
However, conventional interferon alpha is somewhat 
tedious and requires daily or 3 subcutaneous injections a 
week with a high occurrence of side-effects. Furthermore, 
the rate of achieving HBeAg seroconversion in Asian patients 
has been low
 (Conjeevaram and Lok 2003). This difference 
between Asian and Caucasian patients is thought to be 
related to the duration of the chronic state, the difference in 
genotype, and baseline characteristics such as serum alanine 
aminotransaminase (ALT) levels. 
While Asians acquire HBV perinatally, Caucasians   
acquire HBV predominantly in their adolescence or adult-
hood. In perinatally acquired infection, infection is followed 
by a lengthy period of immune tolerance during which the 
HBV DNA is high while the serum ALT levels are normal 
or near normal and liver necroinflammation is minimal (Lai 
et al 1987; Lok et al 1989; Conjeevaram and Lok 2003). In 
the latter, there is more active host immune response directed 
towards clearance of the infection with raised ALT levels
 
(Perillo 1989). These drawbacks with conventional interferon 
alpha therapy have led to the development of pegylated 
interferon alpha. international Journal of Nanomedicine 2006:1(3) 257
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Pegylated interferon
Pegylation
Pegylated interferon alpha-2a (40 kDa) joins a number of 
therapeutic agents that are pegylated by the incorporation of a 
polyethylene moiety into the active product. Pegylation of the 
interferon alpha molecule is undertaken mostly to enhance the 
pharmacokinetic properties of unmodified interferon alpha, 
which will enable once a week dosing. Although a larger 
pegylation molecule can result in better stability and longer 
half-life, it will interfere with the active receptor binding 
(Youngster et al 2002). 
Pegylation may occur at multiple sites of the interferon 
molecule, but pegylation at most of them does not retain the 
biochemical and therapeutic properties. Therefore it is very 
important to strike a balance between the pegylation site, size 
of the molecule, steric properties, and biochemical properties 
(Youngster et al 2002).
For example, the molecular weight of the pegylation chain 
must be greater than 4000 to avoid poisoning by ethylene 
glycol (Working et al 1997). The sites of attachment may 
be more than one single site, but multiple chains may lead 
to steric hindrance and prohibit the binding of the peglyated 
interferon to its effector (Harris et al 2001). The bonds must 
be strong and resistant to degradation (Wang et al 2000). 
The pegylation polymer is usually covalently attached, via 
an amide or urethane bond, to a lysine or histidine residue or 
the N-terminus of the protein. By controlling the reagents, 
condition, and the pH, pegylation of interferon at a specific 
site with a defined pegylated polymer can be achieved 
(Kozlowski et al 2001; Youngster et al 2002).
The first pegylated interferon alpha-2a to be developed 
was 5 kDa in size. However, this drug has limited overall 
clinical and laboratory benefits. Since then, pegylated 
interferon alpha-2a (40 kDa) and pegylated interferon 
alpha-2b (12 kDa) have been developed. As a result of their 
difference in size and structure, these two molecules have 
different in vivo and in vitro characteristics. Pegylated 
interferon alpha-2a (40 kDa) has a longer half-life and is 
mainly catabolized in the liver and has active breakdown 
products. Pegylated interferon alpha-2b (12 kDa) is a smaller 
molecule, has a shorter half-life, and acts as a pro-drug depot 
by slowly releasing interferon (Wang et al 2000; Kozlowski 
et al 2001).
Pegylated interferon alpha-2a (40 kDa) 
The pegylation of interferon alpha-2a involves 2 chains of 
20 kDa polyethylene glycol conjugated to the lysine residues 
(position 31, 121, 131, and 134) of the interferon alpha-2a 
molecule. The plasma level reaches its peak between 72 and 
96 hours after administration and the volume of distribution 
is 8–12 L, suggesting it is highly compartmentalized in 
the intravascular space. The clearance half-life is 40–80 
hours. The serum antiviral activity, as measured by the 2’-5’ 
oligoadenylate synthetase activity, peaks at 24–48 hours after 
administration and it remains high for 1 week (Reddy 2004). 
Because of its highly intravascular compartmentalization, 
dose adjustment according to body weight is not necessary 
(Table 1).
Pegylated interferon alpha-2a (40 kDa) 
in HBeAg positive patients
When pegylated interferon alpha-2a was tested in a phase 
II study at 90, 180, and 270 µg/week for 24 weeks against 
conventional interferon alpha-2a, the HBeAg seroconversions 
were 37%, 35%, 29%, and 25% respectively (Cooksley et 
al 2003). The combined response (HBeAg loss, HBV DNA 
suppression < 500 000 copies/mL, ALT normalization) was 
higher in all pegylated interferon alpha-2a doses combined 
(24% vs 12%). The response was still higher among patients 
that were difficult to treat: 27% in patients with < 2 times 
upper limit of normal (ULN) of baseline ALT vs 11% of 
interferon alpha-2a; 20% vs 0% in patients with HBV 
DNA >11.0 log copies/mL. The side-effects seemed to be 
dose-dependent and occurred more often in the 270-µg and 
180-µg groups. However, no difference in side-effect could 
be observed when the 270-µg group was compared with the 
180-µg group.
The beneficial effect of pegylated interferon alpha-2a 
Table 1  Comparison between conventional interferon alpha-2a and pegylated interferon alpha-2a 
  Conventional interferon  Pegylated interferon
  alpha 2a   alpha-2a
Time to peak serum level (hours)  7.3–12   80
Absorption half-life (hour)  2.3  50
volume of distribution (L)  31–73  8–12 
Clearance (L/hour)  6.6–29.2  0.06–0.10
elimination half-life (hours)  3–8  65international Journal of Nanomedicine 2006:1(3) 258
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was further substantiated in 2 multinational phase III studies 
(Marcellin et al 2004; Lau, Piratvisuth, et al 2005). In the 
phase III HBeAg positive study, 814 HBeAg positive chronic 
HBV-infected patients were randomized to receive either 
pegylated interferon alpha-2a 180 µg weekly monotherapy, 
pegylated interferon alpha-2a 180 µg weekly plus lamivudine 
100 mg daily combination therapy, or lamivudine 100 mg 
daily for a total of 48 weeks and assessed at 24 weeks after 
the end of therapy (Lau, Piratvisuth, et al 2005). More than 
85% of patients in this study were Asians, and the mean 
HBV DNA was 9.9–10.1 log copies/mL. About 15%–18% 
of patients had severe fibrosis or cirrhosis by liver biopsy 
at baseline, and 9%–15% had received lamivudine therapy 
and 2%–3% of patients had previously been treated with 
conventional interferon alpha-2a.
HBeAg seroconversion and suppression of HBV DNA to 
less than 100 000 copies/mL were significantly higher with 
pegylated interferon alpha-2a monotherapy and pegylated 
interferon alpha-2a plus lamivudine combination therapy 
when compared with lamivudine monotherapy (Table 2). 
More importantly, loss of HBsAg with development of 
hepatitis B surface antibody (anti-HBs) was achieved in 8 
of the 271 patients (3.0%) on pegylated interferon alpha-2a 
monotherapy, 8 of the 271 patients (3.0%) on pegylated 
interferon alpha-2a plus lamivudine combination therapy, and 
none of the 272 patients (0%) on lamivudine monotherapy 
(p=0.004 for both comparisons) (Lau, Piratvisuth, et al 2005).
Pegylated interferon alpha-2a (40 kDa) 
in HBeAg negative patients
In another randomized, partially double-blind phase III 
controlled study, 537 HBeAg negative chronic HBV patients 
were randomized to receive either pegylated interferon alpha-
2a 180 µg weekly, combination pegylated interferon alpha-2a 
180 µg weekly plus lamivudine 100 mg daily, or lamivudine 
100 mg daily monotherapy for 48 weeks and followed up for 
another 24 weeks after therapy (Marcellin et al 2004). Patients 
were included into this trial if they had been HBeAg negative 
and anti-HBe positive for at least 6 months, had an HBV DNA 
of more than 100 000 copies/mL, a serum ALT level greater 
than 1 but less than 10 times the upper limit of normal, and 
had findings on liver biopsy within the previous 24 months 
showing evidence of prominent necroinflammatory activity. 
The 2 primary end points assessed at 24 weeks after the 
completion of therapy of this study were normalization of 
serum ALT and suppression of HBV DNA below 20 000 
copies/mL. 
After 48 weeks of therapy, suppression of serum HBV 
DNA from baseline was the greatest with combination 
pegylated interferon alpha-2a plus lamivudine therapy. On 
the other hand, suppression of HBV DNA from the baseline 
was similar in patients on pegylated interferon alpha-2a 
monotherapy and lamivudine monotherapy.
At 24 weeks after therapy, normalization of serum ALT 
was higher in patients receiving pegylated interferon alpha-2a 
monotherapy (59%) and combination pegylated interferon 
alpha-2a plus lamivudine therapy (60%) when compared with 
those receiving lamivudine monotherapy (44%). Virologic 
response was also higher in patients receiving pegylated 
interferon alpha-2a monotherapy (43%) and combination 
pegylated interferon alpha-2a plus lamivudine (44%) than 
in patients receiving lamivudine monotherapy (29%). 
Suppression of HBV DNA to below 400 copies/mL at week 
72 was also higher in those receiving pegylated interferon 
alpha-2a monotherapy (19%) and combination pegylated 
interferon alpha-2a plus lamivudine therapy (20%) when 
compared with those on lamivudine monotherapy alone (7%) 
(Marcellin et al 2004). 
Table 2  efficacy of pegylated interferon alpha-2a on hepatitis B e Antigen positive chronic hepatitis B virus patients
  Pegylated interferon  Pegylated interferon   Lamivudine 
  alpha-2a plus   alpha-2a plus   (n = 272) 
  placebo  lamivudine
  (n = 271)  (n = 271) 
Co-primary endpoints     
HBeAg  32% (p < 0.001)
a  27% (p = 0.023)  19%
seroconversion 
HBv DNA
< 100 000 copies/mL  32% (p = 0.012)
a  34% (p = 0.003)
a  22%
Secondary endpoints     
HBeAg loss  34% (p < 0.001)
a  28% (p = 0.043)
a  21%
ALT normalization  41% (p = 0.002)
a  39% (p = 0.006)
a  28%
Adapted from Lau, Piratvisuth, et al (2005).
a compared with lamivudine therapy. international Journal of Nanomedicine 2006:1(3) 259
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Most importantly, loss of HBsAg occurred in 7 patients 
receiving pegylated interferon alpha-2a monotherapy 
(5 Asians and 2 Caucasians) and in 5 patients receiving 
combination pegylated interferon alpha-2a plus lamivudine 
therapy (4 Asians and 1 Caucasian). This was significantly 
higher compared with lamivudine monotherapy alone (n = 0) 
(p = 0.007 and p = 0.030 respectively).  HBsAg clearance with 
development of anti-HBs occurred in 8 patients on pegylated 
interferon alpha-2a (5 on pegylated interferon alpha-2a 
monotherapy and 3 on combination pegylated interferon 
alpha-2a plus lamivudine therapy) compared with none 
in patients receiving lamivudine monotherapy (p = 0.029) 
(Marcellin et al 2004).
Combination pegylated interferon 
alpha-2a (40 kDa) plus lamivudine 
therapy
Disappointingly, data generated from 2 studies do not 
support the use of combination therapy with pegylated 
interferon alpha-2a and lamivudine in terms of achieving a 
sustained off-treatment response (Marcellin et al 2004; Lau, 
Piratvisuth, et al 2005). In both phase III HBeAg positive and 
HBeAg negative studies, the degree of viral load suppression 
at the end of treatment was higher in those on a lamivudine-
containing regimen than those on pegylated interferon 
alpha-2a alone (7.2 log vs 4.5 log respectively in the HBeAg 
positive study and 5.0 log vs 4.1 log respectively in the 
HBeAg negative study), but the rate of sustained disease 
remission was higher in the latter (Marcellin et al 2004; 
Lau, Piratvisuth, et al 2005).
 This finding suggests that the 
mechanism of viral load reduction, in addition to the degree 
of viral suppression, is an important factor affecting sustained 
disease remission. However, one benefit of combination 
pegylated interferon alpha-2a plus lamivudine therapy is a 
lower YMDD mutation (1%–4%) compared with lamivudine-
only therapy (18%–27%) (Germanidis et al 2004).
Predictors of response 
Patients infected with genotype A had the highest HBeAg 
seroconversion at 24 weeks after pegylated interferon alpha-
2a (± lamivudine) therapy (52%) compared with patients 
infected with genotype B or C (30%–31%), but the rate of 
the gentotype C group was still better than with lamivudine-
only therapy
  (Chow et al 2005). 
Patients with a high baseline ALT level and low HBV 
DNA are also more likely to achieve sustained response 
with pegylated interferon alpha-2a therapy. High baseline 
ALT levels (> 5 times ULN) and low HBV DNA (< 9.1 log 
copies/mL) achieved HBeAg seroconversion rates of 41% 
and 53% respectively
 (Chow et al 2005). The authors also 
found that a more profound HBeAg suppression at week 12 
of therapy (less than 10 IU/mL) was associated with a higher 
HBeAg seroconversion (53%).
A prior use of other antiviral therapies (lamivudine, or 
conventional interferon alpha) does not preclude patients 
from treatment with pegylated interferon alpha-2a, as the 
response rates were similar to those without such use before
 
(Lau, Luo, et al 2005).
Durability of off-therapy sustained 
response
In a longer follow-up study on the durability of off-therapy 
response with pegylated interferon alpha-2a (Marcellin et al 
2005), 177 HBeAg negative patients with biochemical and 
virological response at 6 months after the completion of 48 
weeks of pegylated interferon  alpha-2a were rolled over into 
a long-term observational study. The rates of biochemical 
and virologic response measured 12 months after the end of 
treatment with pegylated interferon alpha-2a monotherapy 
were similar to those reported 6 months after the end of 
treatment: 59% vs 59% for ALT normalization; 42% vs 
43% for HBV DNA < 20 000 copies/mL; and 17% vs 19% 
for HBVDNA < 400 copies/mL. In a subanalysis of those 
patients who responded to pegylated interferon alpha-2a 
monotherapy at the end of treatment, more than half (75%) 
had HBV-DNA levels < 100 000 copies/mL for most of the 
12 month follow-up; 30% had HBV-DNA levels < 20 000 
copies/mL, and 15% had HBV-DNA levels permanently 
< 400 copies/mL.
effect on liver histology
The effect of pegylated interferon alpha-2a on liver histology 
was analyzed by Lau et al and Cooksley et al (Cooksley 
et al 2005; Lau, Cooksley, et al 2005). Both studies found 
that pegylated interferon alpha-2a therapy can result in 
histological improvement (defined as drop of 2 points in 
the Modified Histologic Activity index) (Ishak et al 1995). 
Forty-nine percent of HBeAg positive and 59% of HBeAg 
negative patients treated with pegylated interferon alpha-2a 
had histological improvement on second liver biopsy at 24 
weeks after the end of therapy (Cooksley et al 2005).
Histologic improvement is more pronounced in patients 
with virological response. Thus, HBeAg positive patients who 
had achieved ALT normalization, HBV DNA suppression, international Journal of Nanomedicine 2006:1(3) 260
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and HBeAg seroconversion are more likely to have histologic 
improvement. Similarly, HBeAg negative patients with 
HBV DNA suppression or ALT normalization also showed 
improvement in liver histology. HBeAg negative patients 
achieving a combined response (normalization of serum ALT 
and suppression of HBV DNA) had a higher histological 
response (78% vs 49%) (Lau, Cooksley, et al 2005). 
Adverse effects
The drop-out rates were low in both phase III studies 
(2%–7%). Most patients (about 80%) finished the prescribed 
dose (Lau, Luo, et al 2005). More patients given pegylated 
interferon alpha-2a suffered from at least 1 adverse effect 
(88%–89% vs 48%–56%). Most of them had fever, fatigue, 
headache, myalgia, alopecia, and injection site reaction. 
About 4%–6% of patients had serious adverse effects as 
a result of pegylated interferon alpha-2a monotherapy and 
pegylated interferon alpha-2a plus lamivudine combination 
therapy, and 2%–3% of lamivudine monotherapy had a   
serious adverse effect. Four deaths occurred in the 
combination therapy but 3 of them were not related to the 
treatment. The only death that was probably related was the 
development of thrombotic thrombocytopenia purpura. Two 
patients in the lamivudine monotherapy had liver failure 
resulting in 1 liver transplantation and 1 death.
Optimal duration of therapy with 
pegylated interferon alpha-2a (40 kDa)
Two studies have demonstrated the efficacy of 48 weeks of 
pegylated interferons alpha-2a either as monotherapy or in 
combination with lamivudine for the treatment of HBeAg 
positive and negative chronic HBV infection (Cooksley et al 
2003; Marcellin et al 2004; Lau, Piravisuth, et al 2005), but it 
is uncertain if a shorter duration of treatment with pegylated 
interferons will affect the sustained virological response rate. 
This is because the current licensed duration of therapy with 
conventional interferon alpha is 16–24 weeks. At the moment, 
no direct comparison between 24 weeks and 48 weeks of 
pegylated interferon alpha for chronic HBV infection has 
been performed.  
In a recent review of our experience in treating HBeAg 
positive Chinese patients in Hong Kong with either 48 weeks 
of pegylated interferon alpha-2a or 24 weeks of pegylated 
interferon alpha-2b, we found that those treated with 48 
weeks of pegylated interferon alpha-2a  had a higher sustained 
virological response, defined as HBeAg seroconversion with 
serum HBV DNA less than 10
5 copies/mL at week 72 (34% 
vs 8%  respectively, p = 0.04) (Hui et al 2006). However, 
owing to the small sample size, the use of different pegylated 
interferon alphas and the retrospective nature of this study, the 
results should be interpreted with caution and show the need 
for a large-scale randomized prospective study comparing 
24 with 48 weeks of pegylated interferon alpha in order to 
determine its optimal duration of therapy.
Conclusions
Pegylated interferon alpha-2a will have an important role 
in the treatment of chronic HBV infection. The choice of 
pegylated interferon alpha-2a as a first-line therapy for 
chronic HBV is based mostly on its efficacy in inducing off-
therapy sustained disease remission (Marcellin et al 2004; 
Lau, Piratvisuth, et al 2005). Newer nucleoside–nucleotide 
analogs such as entecavir and telbivudine with a more 
pronounced and rapid suppression of HBV replication are 
expected to be approved later. Higher or more pronounced 
suppression of HBV DNA may be achievable with these 
drugs. However, their rates of HBeAg seroconversion after 
48 weeks of therapy do not seem to be more pronounced 
than that achieved with lamivudine or adefovir dipivoxil. It 
is also uncertain if these new nucleoside–nucleotide analogs 
can lead to off-therapy sustained disease remission. A finite 
course of pegylated interferon alpha-2a with an increased 
rate of virologic and biochemical response coupled with its 
improved off-therapy response makes pegylated interferon 
alpha-2a a first-line therapy for chronic HBV . 
In those who do not respond to pegylated interferon 
alpha-2a, long-term maintenance therapy with a nucleoside–
nucleotide analog either as monotherapy or combination 
therapy may have to be considered. However, drug resistance 
and its avoidance is a major obstacle to maintenance therapy. 
New nucleoside–nucleotide analogs such as entecavir and 
telbivudine have a more pronounced viral suppression of 
HBV replication, but their rates of viral resistance during 
long-term therapy have yet to be evaluated and may be a 
frequent problem, making them unsuitable for effective 
long-term therapy (Hadziyannis 2003; Hadziyannis and 
Papatheodoridis 2003). Hence, control of chronic HBV may 
require long-term therapy consisting of combination therapy. 
The challenge is to find the correct combination (Shaw and 
Locarnini 2000).international Journal of Nanomedicine 2006:1(3) 261
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